e-learning
resources
Munich 2014
Sunday, 07.09.2014
Pathology and prognostic factors of thoracic tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer
M. Petrovic, I. Cekerevac, D. Petrovic, R. Vucic, I. Simic (Kragujevac, Republic Of Serbia)
Source:
International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Session:
Pathology and prognostic factors of thoracic tumours
Session type:
Poster Discussion
Number:
516
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Petrovic, I. Cekerevac, D. Petrovic, R. Vucic, I. Simic (Kragujevac, Republic Of Serbia). Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Eur Respir J 2014; 44: Suppl. 58, 516
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Definition and history of sarcoidosis
Related content which might interest you:
The value of miR221 and miR222 as a biomarker in non small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Methilation status in EBUS-NA samples of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Metabolomic analysis of serum samples from patients with lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Polymorphism of
HLA-G
gene promotor in patients with non small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Relationship between risk factors for lung cancer and tumor size
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
PIWI proteins as prognostic markers in non small cell lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Serum osteopontin as a prognostic marker in patients with lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Symptom-to-treatment intervals in lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
MUC1 gene polymorphism and serum KL-6 in lung adenocarcinoma
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
CD33
+
CD14
-
CD11b
+
CD66b
+
CD15
+
VEGFR-1
hi
myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Association between leptin and risk of lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Lactat-dehydrogenase, C-reactive protein and white blood cell count are prognostic factors in advanced small cell lung cancer (SCLC)
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept